Novo Nordisk contracts South Africa's Aspen to produce insulin for African nations
Novo Nordisk has contracted Aspen Pharmacare to produce human insulin on its behalf in South Africa for export to African countries through a low-cost government tender system, the Danish drugmaker said on Tuesday.
Announcing the deal on the sidelines of the United Nations General Assembly in New York, Novo said the contract will lead to the production of 16-million vials of insulin next year, marking its "expanded commitment" to improving access to life-saving insulin to people living with diabetes in Africa.
Novo said the amount that Aspen will produce next year under the contract equates to the yearly consumption of 1.1-million people with type 1 and type 2 diabetes, adding that it currently reaches 500,000 people with diabetes across sub-Saharan Africa.
By 2026, the amount of insulin produced will equate to the yearly consumption of 4.1 million people across the continent, it said.
"Especially in lower and middle income countries, diabetes is fundamentally a tragedy," Katrine DiBona, Novo's corporate vice president for global public affairs and sustainability, said in an interview. She cited a company estimate that 60 million people globally need insulin but cannot access it.
Novo became Europe's most valuable company earlier this month on booming sales of its obesity and type 2 diabetes drugs. It currently has a market capitalisation of about $420-billion.
Novo said the Aspen-produced insulin will be distributed to health authorities and non-governmental organisations through a tender system with a guaranteed ceiling price of $3 per vial. It did not release further financial details about the contract.
The deal could help Aspen, Africa's biggest drugmaker, utilise the expanded manufacturing capacity it built during the Covid-19 pandemic. Aspen invested about $540-million to expand facilities in South Africa and France, but orders for its vaccine failed to materialise.
That left the increased capacities loss-making, Aspen's CEO told Reuters last month after the company announced it had finally secured agreements with three global companies to produce their drugs at its French facility.
Novo chose Aspen as its partner due to its credibility as a drug manufacturer, DiBona said.
Comments
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation